RecruitingNCT06697093

Polish Nationwide Registry of Diagnostics, Treatment and Outcome in Patients With Cardiogenic Shock

Polish Nationwide Registry of Diagnostics, Treatment and Outcome in Patients With Cardiogenic Shock CaS-POL


Sponsor

Wroclaw Medical University

Enrollment

500 participants

Start Date

Apr 1, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The registry objective is to get information on current epidemiology, diagnostics, treatment and outcome in patients with cardiogenic shock in Poland. Obtained information will help to plan the nationwide initiative for modern cardiogenic shock treatment with established place for mechanical circulatory support. It is hypothesized that the treatment and outcome of cardiogenic shock, including mechanical circulatory support, are currently poor in Poland and should be improved. Unfortunately, without status quo data, efficient planning for its improvement cannot be conducted, hence the CaS-POL registry initiative.


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Cardiogenic shock patients of all etiologies in SCAI stage B, C, D, E.
  • age > 18 years old
  • persistent hemodynamic failure defined as systolic blood pressure of <90 mmHg for ≥ 30 minutes or the requirement for inotropic or vasopressor agents with evidence of hypoperfusion of the peripheral organs

Exclusion Criteria4

  • patients without return of spontaneous circulation who were considered to extracorporeal cardiopulmonary resuscitation (ECPR)
  • primary septic, anaphylactic, hypovolemic shock
  • post-operative cardiogenic shock
  • end-stage of heart failure disqualified from mechanical circulatory support and heart transplantation

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(2)

Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland

Wroclaw, Lower Silesian Voivodeship, Poland

Wroclaw Medical University

Wroclaw, Poland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06697093


Related Trials